Receptor diagnostics for advanced breast cancer. Results of a pilot clinical trial are promising

- This achievement is of special significance to me, since my adventure with the affibody-based ABY-025 radiolabeled tracer began back in 2006 in Jack Capala's lab at the National Cancer Institute in Bethesda, USA. I am proud that I was able to apply this tracer clinically," says Prof. Gabriela Kramer-Marek, head of the Department of PET Radiopharmacy and Laboratory Imaging at the Gliwice branch of the Maria Sklodowska-Curie National Cancer Institute - National Research Institute.

Prof. Gabriela Kramer-Marek, along with a team of clinicians and scientists from the National Cancer Institute in Gliwice: Anna Kastelik-Hryniewiecka, M.D., from the Department of PET Radiopharmacy and Laboratory Imaging, Michal Jarząb, M.D., Ph. Marcin Kubeczko of the Center for Breast Disease Diagnosis and Treatment, and Andrea d'Amico, M.D., and Izabela Gorczewska, M.D., of the Department of Nuclear Medicine and Oncologic Endocrinology...